Video

Abzena Capacity Update October 2025: ADC

Source: Abzena

This presentation highlights ThioBridge™ as an efficient site-specific conjugation technology to generate ADCs and other conjugate modalities such as oligoconjugates (AOCs) and conjugates for diagnostics applications.

Gain insight into:

  • ThioBridge™ conjugation technology insights. How the technology works, and its advantages over stochastic conjugation technologies.
  • Modulation of Drug-Antibody Ratio (DAR) using ThioBridge™ as an effective feature to optimize therapeutic activity.
  • In vitro and in vivo stability of ADCs generated using ThioBridge™
  • Optimization of linker architecture to enhance in vivo efficacy of ThioBridge™ ADCs. In vivo data for relevant ADCs generated using ThioBridge™ technology
  • ThioBridge™ linker-payload and ADC manufacturing considerations.

access the Video!

Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Outsourced Pharma? Subscribe today.

Subscribe to Outsourced Pharma X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Outsourced Pharma

Please tell us more about you so that we can customize our newsletters to your specific interests:

What topics interest you? (Check all that apply.)

Abzena